Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy

Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this multicenter retrospective study, we sought to confirm this observation by evaluating survival outcomes among patients with relapsed/refractory DHL an...

Full description

Saved in:

Bibliographic Details
Published in:	Blood cancer journal (New York) Vol. 15; no. 1; pp. 43 - 7
Main Authors:	Karmali, Reem, Shouse, Geoffrey, Torka, Pallawi, Moyo, Tamara K., Romancik, Jason, Barta, Stefan K., Bhansali, Rahul, Cohen, Jonathon B., Shah, Nirav N., Zurko, Joanna, Kenkre, Vaishalee P., Hess, Brian, Stephens, Deborah M., Fitzgerald, Lindsey, Ollila, Thomas, Tabiti, Bukky, Roy, Ishan, Ma, Shuo, Winter, Jane, Pro, Barbara, Moreira, Jonathan, Danilov, Alexey V., David, Kevin, Gordon, Leo I., Epperla, Narendranath
Format:	Journal Article
Language:	English
Published:	London Nature Publishing Group UK 26.03.2025 Springer Nature B.V Nature Publishing Group
Subjects:	692/699/1541/1990/291/1621/1915 692/699/67/1059/2325 692/700/565/251 Adult Aged Aged, 80 and over Antigens, CD19 - immunology Biomedical and Life Sciences Biomedicine Cancer Research Female Hematology Humans Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - immunology Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - therapy Male Medical prognosis Middle Aged Oncology Prognosis Receptors, Chimeric Antigen Retrospective Studies Treatment Outcome Young Adult
ISSN:	2044-5385, 2044-5385
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Abstract	Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this multicenter retrospective study, we sought to confirm this observation by evaluating survival outcomes among patients with relapsed/refractory DHL and DEL treated with CART and evaluate outcomes of relapse post-CART. A total of 408 adult patients with relapsed/refractory DLBCL from 13 academic centers were included based on the availability of DHL and DEL. All 408 patients were included in the DHL ( n = 80) vs non-DHL ( n = 328) analysis, while 333 patients were included in the analysis of DHL ( n = 80) vs DEL ( n = 74) vs non ( n = 179). On MVA, there were no differences for PFS for DHL vs non-DHL (HR 0.8, 95%CI 0.5–1.3, p = 0.35) or DHL vs DEL vs other (three-way p value, p = 0.5). Response rates and toxicities were similar among groups. Patients with DEL had the highest relapse rates post-CART, while DHL had the worst overall survival after CART relapse. In sum, our data support the notion that CART cell therapy can overcome the poor prognostic impact of DHL and DEL DLBCL in the relapsed/refractory setting. Additionally, patients with DHL that relapse after CART have a very poor prognosis.
AbstractList	Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this multicenter retrospective study, we sought to confirm this observation by evaluating survival outcomes among patients with relapsed/refractory DHL and DEL treated with CART and evaluate outcomes of relapse post-CART. A total of 408 adult patients with relapsed/refractory DLBCL from 13 academic centers were included based on the availability of DHL and DEL. All 408 patients were included in the DHL (n = 80) vs non-DHL (n = 328) analysis, while 333 patients were included in the analysis of DHL (n = 80) vs DEL (n = 74) vs non (n = 179). On MVA, there were no differences for PFS for DHL vs non-DHL (HR 0.8, 95%CI 0.5-1.3, p = 0.35) or DHL vs DEL vs other (three-way p value, p = 0.5). Response rates and toxicities were similar among groups. Patients with DEL had the highest relapse rates post-CART, while DHL had the worst overall survival after CART relapse. In sum, our data support the notion that CART cell therapy can overcome the poor prognostic impact of DHL and DEL DLBCL in the relapsed/refractory setting. Additionally, patients with DHL that relapse after CART have a very poor prognosis. Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this multicenter retrospective study, we sought to confirm this observation by evaluating survival outcomes among patients with relapsed/refractory DHL and DEL treated with CART and evaluate outcomes of relapse post-CART. A total of 408 adult patients with relapsed/refractory DLBCL from 13 academic centers were included based on the availability of DHL and DEL. All 408 patients were included in the DHL (n = 80) vs non-DHL (n = 328) analysis, while 333 patients were included in the analysis of DHL (n = 80) vs DEL (n = 74) vs non (n = 179). On MVA, there were no differences for PFS for DHL vs non-DHL (HR 0.8, 95%CI 0.5-1.3, p = 0.35) or DHL vs DEL vs other (three-way p value, p = 0.5). Response rates and toxicities were similar among groups. Patients with DEL had the highest relapse rates post-CART, while DHL had the worst overall survival after CART relapse. In sum, our data support the notion that CART cell therapy can overcome the poor prognostic impact of DHL and DEL DLBCL in the relapsed/refractory setting. Additionally, patients with DHL that relapse after CART have a very poor prognosis.Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this multicenter retrospective study, we sought to confirm this observation by evaluating survival outcomes among patients with relapsed/refractory DHL and DEL treated with CART and evaluate outcomes of relapse post-CART. A total of 408 adult patients with relapsed/refractory DLBCL from 13 academic centers were included based on the availability of DHL and DEL. All 408 patients were included in the DHL (n = 80) vs non-DHL (n = 328) analysis, while 333 patients were included in the analysis of DHL (n = 80) vs DEL (n = 74) vs non (n = 179). On MVA, there were no differences for PFS for DHL vs non-DHL (HR 0.8, 95%CI 0.5-1.3, p = 0.35) or DHL vs DEL vs other (three-way p value, p = 0.5). Response rates and toxicities were similar among groups. Patients with DEL had the highest relapse rates post-CART, while DHL had the worst overall survival after CART relapse. In sum, our data support the notion that CART cell therapy can overcome the poor prognostic impact of DHL and DEL DLBCL in the relapsed/refractory setting. Additionally, patients with DHL that relapse after CART have a very poor prognosis. Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this multicenter retrospective study, we sought to confirm this observation by evaluating survival outcomes among patients with relapsed/refractory DHL and DEL treated with CART and evaluate outcomes of relapse post-CART. A total of 408 adult patients with relapsed/refractory DLBCL from 13 academic centers were included based on the availability of DHL and DEL. All 408 patients were included in the DHL ( n = 80) vs non-DHL ( n = 328) analysis, while 333 patients were included in the analysis of DHL ( n = 80) vs DEL ( n = 74) vs non ( n = 179). On MVA, there were no differences for PFS for DHL vs non-DHL (HR 0.8, 95%CI 0.5–1.3, p = 0.35) or DHL vs DEL vs other (three-way p value, p = 0.5). Response rates and toxicities were similar among groups. Patients with DEL had the highest relapse rates post-CART, while DHL had the worst overall survival after CART relapse. In sum, our data support the notion that CART cell therapy can overcome the poor prognostic impact of DHL and DEL DLBCL in the relapsed/refractory setting. Additionally, patients with DHL that relapse after CART have a very poor prognosis. Abstract Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this multicenter retrospective study, we sought to confirm this observation by evaluating survival outcomes among patients with relapsed/refractory DHL and DEL treated with CART and evaluate outcomes of relapse post-CART. A total of 408 adult patients with relapsed/refractory DLBCL from 13 academic centers were included based on the availability of DHL and DEL. All 408 patients were included in the DHL (n = 80) vs non-DHL (n = 328) analysis, while 333 patients were included in the analysis of DHL (n = 80) vs DEL (n = 74) vs non (n = 179). On MVA, there were no differences for PFS for DHL vs non-DHL (HR 0.8, 95%CI 0.5–1.3, p = 0.35) or DHL vs DEL vs other (three-way p value, p = 0.5). Response rates and toxicities were similar among groups. Patients with DEL had the highest relapse rates post-CART, while DHL had the worst overall survival after CART relapse. In sum, our data support the notion that CART cell therapy can overcome the poor prognostic impact of DHL and DEL DLBCL in the relapsed/refractory setting. Additionally, patients with DHL that relapse after CART have a very poor prognosis.
ArticleNumber	43
Author	Torka, Pallawi Ma, Shuo Stephens, Deborah M. Romancik, Jason Shah, Nirav N. Gordon, Leo I. Roy, Ishan Karmali, Reem Zurko, Joanna Moreira, Jonathan Shouse, Geoffrey Epperla, Narendranath Cohen, Jonathon B. Hess, Brian Fitzgerald, Lindsey Moyo, Tamara K. Ollila, Thomas David, Kevin Bhansali, Rahul Pro, Barbara Winter, Jane Barta, Stefan K. Tabiti, Bukky Kenkre, Vaishalee P. Danilov, Alexey V.
Author_xml	– sequence: 1 givenname: Reem orcidid: 0000-0003-0984-4376 surname: Karmali fullname: Karmali, Reem email: Reem.Karmali@nm.org organization: Robert H Lurie Comprehensive Cancer Center, Northwestern University – sequence: 2 givenname: Geoffrey orcidid: 0000-0002-7917-5713 surname: Shouse fullname: Shouse, Geoffrey organization: City of Hope Comprehensive Cancer Center – sequence: 3 givenname: Pallawi orcidid: 0000-0002-1681-5883 surname: Torka fullname: Torka, Pallawi organization: Memorial Sloan Kettering Cancer Center – sequence: 4 givenname: Tamara K. surname: Moyo fullname: Moyo, Tamara K. organization: Levine Cancer Institute, Atrium Health – sequence: 5 givenname: Jason orcidid: 0000-0003-0054-9362 surname: Romancik fullname: Romancik, Jason organization: Winship Cancer Institute, Emory University – sequence: 6 givenname: Stefan K. orcidid: 0000-0002-3280-5271 surname: Barta fullname: Barta, Stefan K. organization: Abramson Cancer Center, University of Pennsylvania – sequence: 7 givenname: Rahul orcidid: 0000-0002-3616-7393 surname: Bhansali fullname: Bhansali, Rahul organization: Abramson Cancer Center, University of Pennsylvania – sequence: 8 givenname: Jonathon B. surname: Cohen fullname: Cohen, Jonathon B. organization: Winship Cancer Institute, Emory University – sequence: 9 givenname: Nirav N. orcidid: 0000-0002-4336-1071 surname: Shah fullname: Shah, Nirav N. organization: MCW Cancer Center, Medical College of Wisconsin – sequence: 10 givenname: Joanna surname: Zurko fullname: Zurko, Joanna organization: Carbone Cancer Center, University of Wisconsin–Madison – sequence: 11 givenname: Vaishalee P. surname: Kenkre fullname: Kenkre, Vaishalee P. organization: Carbone Cancer Center, University of Wisconsin–Madison – sequence: 12 givenname: Brian surname: Hess fullname: Hess, Brian organization: Hollings Cancer Center, Medical University of South Carolina – sequence: 13 givenname: Deborah M. surname: Stephens fullname: Stephens, Deborah M. organization: Lineberger Comprehensive Cancer Center, University of North Carolina – sequence: 14 givenname: Lindsey surname: Fitzgerald fullname: Fitzgerald, Lindsey organization: Huntsman Cancer Institute, University of Utah – sequence: 15 givenname: Thomas orcidid: 0000-0003-0102-6491 surname: Ollila fullname: Ollila, Thomas organization: Lifespan Cancer Institute, Brown University – sequence: 16 givenname: Bukky surname: Tabiti fullname: Tabiti, Bukky organization: Robert H Lurie Comprehensive Cancer Center, Northwestern University – sequence: 17 givenname: Ishan orcidid: 0000-0002-9109-0421 surname: Roy fullname: Roy, Ishan organization: Robert H Lurie Comprehensive Cancer Center, Northwestern University, Shirley Ryan Ability Lab – sequence: 18 givenname: Shuo orcidid: 0000-0002-6139-5486 surname: Ma fullname: Ma, Shuo organization: Robert H Lurie Comprehensive Cancer Center, Northwestern University – sequence: 19 givenname: Jane surname: Winter fullname: Winter, Jane organization: Robert H Lurie Comprehensive Cancer Center, Northwestern University – sequence: 20 givenname: Barbara surname: Pro fullname: Pro, Barbara organization: Herbert Irving Comprehensive Cancer Center, Columbia University – sequence: 21 givenname: Jonathan surname: Moreira fullname: Moreira, Jonathan organization: Robert H Lurie Comprehensive Cancer Center, Northwestern University – sequence: 22 givenname: Alexey V. orcidid: 0000-0003-4461-0970 surname: Danilov fullname: Danilov, Alexey V. organization: City of Hope Comprehensive Cancer Center – sequence: 23 givenname: Kevin surname: David fullname: David, Kevin organization: Rutgers Cancer Institute of New Jersey, Rutgers University – sequence: 24 givenname: Leo I. orcidid: 0000-0003-1666-7064 surname: Gordon fullname: Gordon, Leo I. organization: Robert H Lurie Comprehensive Cancer Center, Northwestern University – sequence: 25 givenname: Narendranath orcidid: 0000-0002-8216-3457 surname: Epperla fullname: Epperla, Narendranath organization: Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/40140360$$D View this record in MEDLINE/PubMed
BookMark	eNp9Ustu1DAUjVARLaU_wAJZQkJsAn7lYTaomvKoVAkJlbXlONczrpx4sJ2B4etxmhbaLuqNX-ccn3t8nxcHox-hKF4S_I5g1r6PnHDclphWJSa0wmX7pDiimPOyYm11cGd9WJzEeIXzqGoiiHhWHHKcyazGR8WfMz91DtDGJvQG9csGfm8DxOgDcvthu_GDih-QQsPkktUwJghIjcrto43IGxSnsLM75ZCfkvYDRPTLpg1anRFR9jaATtCj1el3dFlqcA6lDQS13b8onhrlIpzczMfFj8-fLldfy4tvX85XpxelrjhLJWdUm7piHc_FaEI1N5yYzjRMi3zYUdGA6ISogZG246Y3TQe81UIBr-u-YcfF-aLbe3Ult8EOKuylV1ZeH_iwlirkwhxIg-vacK2FyAHxhoumI5rqjipW0ZbWWevjorWdugH6OYyg3D3R-zej3ci130lCRNbjJCu8vVEI_ucEMcnBxjkWNYKfosxFkBaLhs-PvX4AvfJTyMEvqOxIVDPq1V1L_7zc_nEGtAtABx9jACO1TSpZPzu0ThIs546SS0fJ3FHyuqNkm6n0AfVW_VESW0gxg8c1hP-2H2H9BR4n3Qw
CitedBy_id	crossref_primary_10_3389_fimmu_2025_1617589
Cites_doi	10.1182/blood-2020-133820 10.1182/blood-2009-03-212191 10.1016/S0140-6736(20)31366-0 10.1182/blood-2010-03-276246 10.1056/NEJMoa2301665 10.1182/blood-2014-05-578963 10.1002/cncr.31877 10.1016/S1470-2045(18)30864-7 10.1016/S1470-2045(11)70235-2 10.1097/PAS.0b013e31826cebad 10.1200/JCO.22.01725 10.1056/NEJMoa2116133 10.1056/NEJMoa2206913 10.1056/NEJMoa1708566 10.1182/blood-2016-01-643569 10.1038/s41375-022-01620-2 10.1200/JCO.20.03175 10.1200/JCO.2016.70.3660 10.1016/S0140-6736(22)00662-6 10.1182/blood-2012-10-460063 10.1182/bloodadvances.2022008240
ContentType	Journal Article
Copyright	The Author(s) 2025 2025. The Author(s). Copyright Springer Nature B.V. Dec 2025 The Author(s) 2025 2025
Copyright_xml	– notice: The Author(s) 2025 – notice: 2025. The Author(s). – notice: Copyright Springer Nature B.V. Dec 2025 – notice: The Author(s) 2025 2025
DBID	C6C AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 8FI 8FJ 8FK ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH K9. M0S M1P PHGZM PHGZT PIMPY PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS 7X8 5PM DOA
DOI	10.1038/s41408-025-01250-8
DatabaseName	Springer Nature OA Free Journals (ODIN) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Medical Database ProQuest Central Premium ProQuest One Academic (New) Publicly Available Content Database ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic (retired) ProQuest One Academic UKI Edition ProQuest Central China MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals
DatabaseTitle	CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) Publicly Available Content Database ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic
DatabaseTitleList	MEDLINE MEDLINE - Academic Publicly Available Content Database
Database_xml	– sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: PIMPY name: Publicly Available Content Database url: http://search.proquest.com/publiccontent sourceTypes: Aggregation Database
DeliveryMethod	fulltext_linktorsrc
Discipline	Medicine
EISSN	2044-5385
EndPage	7
ExternalDocumentID	oai_doaj_org_article_f066f4cc9901447497b1c2cb2a352826 PMC11947441 40140360 10_1038_s41408_025_01250_8
Genre	Multicenter Study Journal Article
GrantInformation_xml	– fundername: NCI NIH HHS grantid: P30 CA008748
GroupedDBID	0R~ 53G 5VS 7X7 88E 8FI 8FJ AAJSJ AASML ABUWG ACGFS ADBBV AENEX AFKRA AJTQC ALIPV ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BCNDV BENPR BPHCQ BVXVI C6C CCPQU DIK EBLON EBS EJD EMOBN FRP FYUFA GROUPED_DOAJ GX1 HMCUK HYE KQ8 M1P M~E NAO OK1 PHGZT PIMPY PQQKQ PROAC PSQYO RNT RNTTT RPM UKHRP W2D AAYXX AFFHD CITATION PHGZM PJZUB PPXIY SNYQT AARCD CGR CUY CVF ECM EIF NPM 3V. 7XB 8FK AZQEC DWQXO K9. PKEHL PQEST PQUKI PRINS 7X8 PUEGO 5PM
ID	FETCH-LOGICAL-c543t-432cf653b4538c12c4f41fbf73c93b4b297e9b996e318b4fdf7be48c9ae466d73
IEDL.DBID	DOA
ISICitedReferencesCount	5
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001454262900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	2044-5385
IngestDate	Fri Oct 03 12:51:11 EDT 2025 Tue Nov 04 02:03:04 EST 2025 Fri Sep 05 17:49:57 EDT 2025 Tue Oct 07 06:53:53 EDT 2025 Wed Aug 06 16:36:22 EDT 2025 Tue Nov 18 22:27:59 EST 2025 Sat Nov 29 08:08:24 EST 2025 Thu Mar 27 04:14:38 EDT 2025
IsDoiOpenAccess	true
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	1
Language	English
License	2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c543t-432cf653b4538c12c4f41fbf73c93b4b297e9b996e318b4fdf7be48c9ae466d73
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23
ORCID	0000-0002-8216-3457 0000-0003-0984-4376 0000-0002-4336-1071 0000-0003-4461-0970 0000-0002-3616-7393 0000-0003-1666-7064 0000-0002-3280-5271 0000-0003-0102-6491 0000-0002-7917-5713 0000-0003-0054-9362 0000-0002-1681-5883 0000-0002-9109-0421 0000-0002-6139-5486
OpenAccessLink	https://doaj.org/article/f066f4cc9901447497b1c2cb2a352826
PMID	40140360
PQID	3181528956
PQPubID	2041967
PageCount	7
ParticipantIDs	doaj_primary_oai_doaj_org_article_f066f4cc9901447497b1c2cb2a352826 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11947441 proquest_miscellaneous_3181809746 proquest_journals_3181528956 pubmed_primary_40140360 crossref_citationtrail_10_1038_s41408_025_01250_8 crossref_primary_10_1038_s41408_025_01250_8 springer_journals_10_1038_s41408_025_01250_8
PublicationCentury	2000
PublicationDate	2025-03-26
PublicationDateYYYYMMDD	2025-03-26
PublicationDate_xml	– month: 03 year: 2025 text: 2025-03-26 day: 26
PublicationDecade	2020
PublicationPlace	London
PublicationPlace_xml	– name: London – name: United States
PublicationTitle	Blood cancer journal (New York)
PublicationTitleAbbrev	Blood Cancer J
PublicationTitleAlternate	Blood Cancer J
PublicationYear	2025
Publisher	Nature Publishing Group UK Springer Nature B.V Nature Publishing Group
Publisher_xml	– name: Nature Publishing Group UK – name: Springer Nature B.V – name: Nature Publishing Group
References	JS Abramson (1250_CR11) 2020; 396 JR Westin (1250_CR16) 2023; 389 R Alaggio (1250_CR7) 2022; 36 MJ Dickinson (1250_CR21) 2022; 387 C Thieblemont (1250_CR22) 2023; 41 S Hu (1250_CR6) 2013; 121 AM Staiger (1250_CR10) 2017; 35 SJ Schuster (1250_CR12) 2017; 377 SS Neelapu (1250_CR13) 2023; 141 M Hutchings (1250_CR20) 2020; 136 M Pfreundschuh (1250_CR2) 2011; 12 M Kamdar (1250_CR15) 2022; 399 AM Petrich (1250_CR5) 2014; 124 FL Locke (1250_CR14) 2021; 386 JK Godfrey (1250_CR8) 2019; 125 NA Johnson (1250_CR4) 2009; 114 FL Locke (1250_CR17) 2019; 20 RK Pillai (1250_CR9) 2013; 37 1250_CR19 SH Swerdlow (1250_CR3) 2016; 127 B Coiffier (1250_CR1) 2010; 116 J Zurko (1250_CR18) 2023; 7
References_xml	– volume: 136 start-page: 45 year: 2020 ident: 1250_CR20 publication-title: Blood doi: 10.1182/blood-2020-133820 – volume: 114 start-page: 2273 year: 2009 ident: 1250_CR4 publication-title: Blood doi: 10.1182/blood-2009-03-212191 – volume: 396 start-page: 839 year: 2020 ident: 1250_CR11 publication-title: Lancet doi: 10.1016/S0140-6736(20)31366-0 – volume: 116 start-page: 2040 year: 2010 ident: 1250_CR1 publication-title: Blood doi: 10.1182/blood-2010-03-276246 – volume: 389 start-page: 148 year: 2023 ident: 1250_CR16 publication-title: N Engl J Med doi: 10.1056/NEJMoa2301665 – volume: 124 start-page: 2354 year: 2014 ident: 1250_CR5 publication-title: Blood doi: 10.1182/blood-2014-05-578963 – volume: 125 start-page: 1830 year: 2019 ident: 1250_CR8 publication-title: Cancer doi: 10.1002/cncr.31877 – volume: 20 start-page: 31 year: 2019 ident: 1250_CR17 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(18)30864-7 – volume: 12 start-page: 1013 year: 2011 ident: 1250_CR2 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(11)70235-2 – volume: 37 start-page: 323 year: 2013 ident: 1250_CR9 publication-title: Am J Surg Pathol doi: 10.1097/PAS.0b013e31826cebad – volume: 41 start-page: 2238 year: 2023 ident: 1250_CR22 publication-title: J Clin Oncol doi: 10.1200/JCO.22.01725 – volume: 386 start-page: 640 year: 2021 ident: 1250_CR14 publication-title: N Engl J Med doi: 10.1056/NEJMoa2116133 – volume: 387 start-page: 2220 year: 2022 ident: 1250_CR21 publication-title: N Engl J Med doi: 10.1056/NEJMoa2206913 – volume: 377 start-page: 2545 year: 2017 ident: 1250_CR12 publication-title: N Engl J Med doi: 10.1056/NEJMoa1708566 – volume: 127 start-page: 2375 year: 2016 ident: 1250_CR3 publication-title: Blood doi: 10.1182/blood-2016-01-643569 – volume: 36 start-page: 1720 year: 2022 ident: 1250_CR7 publication-title: Leukemia doi: 10.1038/s41375-022-01620-2 – volume: 141 start-page: 2307 year: 2023 ident: 1250_CR13 publication-title: Blood – ident: 1250_CR19 doi: 10.1200/JCO.20.03175 – volume: 35 start-page: 2515 year: 2017 ident: 1250_CR10 publication-title: J Clin Oncol doi: 10.1200/JCO.2016.70.3660 – volume: 399 start-page: 2294 year: 2022 ident: 1250_CR15 publication-title: Lancet doi: 10.1016/S0140-6736(22)00662-6 – volume: 121 start-page: 4021 year: 2013 ident: 1250_CR6 publication-title: Blood doi: 10.1182/blood-2012-10-460063 – volume: 7 start-page: 2657 year: 2023 ident: 1250_CR18 publication-title: Blood Adv doi: 10.1182/bloodadvances.2022008240
SSID	ssj0000561919
Score	2.3813894
Snippet	Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this... Abstract Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this...
SourceID	doaj pubmedcentral proquest pubmed crossref springer
SourceType	Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher
StartPage	43
SubjectTerms	692/699/1541/1990/291/1621/1915 692/699/67/1059/2325 692/700/565/251 Adult Aged Aged, 80 and over Antigens, CD19 - immunology Biomedical and Life Sciences Biomedicine Cancer Research Female Hematology Humans Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Lymphoma, Large B-Cell, Diffuse - genetics Lymphoma, Large B-Cell, Diffuse - immunology Lymphoma, Large B-Cell, Diffuse - mortality Lymphoma, Large B-Cell, Diffuse - therapy Male Medical prognosis Middle Aged Oncology Prognosis Receptors, Chimeric Antigen Retrospective Studies Treatment Outcome Young Adult
SummonAdditionalLinks	– databaseName: Health & Medical Collection dbid: 7X7 link: http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwELagIMSF9yNQkJEQF7AaPxLbXFBZqDhAhVCR9hbFjt2utEpKkkWUX8_Y8W61PHrhmMSRJp7P884MQs8LXricWUd8qR0RJW-I8V4RyYSTjhldm9hd_6M8PFTzuf6cAm5DKqtcy8QoqJvOhhj5HmAPVI0Cc_7N6TcSpkaF7GoaoXEZXQljswPO5VxuYizBOtZUp39lcq72BgEOhSJhhitI5iInaksfxbb9f7M1_yyZ_C1vGtXRwc3__ZBb6EYyRPH-hJzb6JJr76Brn1Kq_S76Caa1WTp8shjxC9xMF-5HrJvterw8AxiE2qLXuMaxKjHQ7Hpcpy4nuPN4WIEgAijjbjUCcW7AIeyLZ--oJpMudQ2e7X_BRyQkEPD0M9jZPfT14P3R7ANJgxqILQQfieDM-rLgRoD4tJRZ4QX1xktuNdw0TEunDXhWIeBqhG-8NE4oq2snyrKR_D7aabvWPUTYqAY8xBo0N7VCanBm6toUKniqeaOpzRBds6uyqYt5GKaxrGI2natqYnEFLK4iiyuVoZebd06nHh4Xrn4bULBZGfpvxxtdf1yl41x5sNS8sDZkFYWQQktDLbOG1aFbDisztLtmfpWEwlCdcz5DzzaP4TiHLa5b162mNSoHJw_WPJggt6FEBG-Yl3mG1BYYt0jdftIuTmLLcEo1UClohl6tcXtO17_34tHFn_EYXWfxKHHCyl20M_Yr9wRdtd_HxdA_jWfxF4YOOww priority: 102 providerName: ProQuest
Title	Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy
URI	https://link.springer.com/article/10.1038/s41408-025-01250-8 https://www.ncbi.nlm.nih.gov/pubmed/40140360 https://www.proquest.com/docview/3181528956 https://www.proquest.com/docview/3181809746 https://pubmed.ncbi.nlm.nih.gov/PMC11947441 https://doaj.org/article/f066f4cc9901447497b1c2cb2a352826
Volume	15
WOSCitedRecordID	wos001454262900001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText	1
inHoldings	1
isFullTextHit
isPrint
journalDatabaseRights	– providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 2044-5385 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000561919 issn: 2044-5385 databaseCode: DOA dateStart: 20110101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVHPJ databaseName: ROAD: Directory of Open Access Scholarly Resources customDbUrl: eissn: 2044-5385 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000561919 issn: 2044-5385 databaseCode: M~E dateStart: 20100101 isFulltext: true titleUrlDefault: https://road.issn.org providerName: ISSN International Centre – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 2044-5385 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000561919 issn: 2044-5385 databaseCode: 7X7 dateStart: 20240101 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: eissn: 2044-5385 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000561919 issn: 2044-5385 databaseCode: BENPR dateStart: 20240101 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest – providerCode: PRVPQU databaseName: Publicly Available Content Database customDbUrl: eissn: 2044-5385 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0000561919 issn: 2044-5385 databaseCode: PIMPY dateStart: 20240101 isFulltext: true titleUrlDefault: http://search.proquest.com/publiccontent providerName: ProQuest
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9QwELagINQL4lkCZWUkbmA1fiS2ubXLViCxq1VVpOUUxY6trrTaoH1U7YXfztjOLl2eFy5RZDvKZGbs8WdPPiP0uuCFy5l1xJfaEVHyhhjvFZFMOOmY0bWJ7Pqf5GikJhM9vnHUV8gJS_TASXFHHmKiF9aG_RshpNDSUMusYXXgJWGRbDuX-gaYSqzeAAyo7v6Sybk6WgqAEoqE01thTC5yonYiUSTs_90s89dkyZ92TGMgOn2A7nczSHycJH-Ibrn5I3Rv2O2RP0ZXMCc2M4cvpivcpFt3FdNd2wWeXYP1QkrQO1zjmEwYXugWuO7ISXDr8XIN4wd4IG7XK3BIt8RhtRb331NNUgh0De4fn-FzEtb9cfqH6_oJ-nw6OO9_IN35CsQWgq-I4Mz6suBGwKhnKbPCC-qNl9xqKDRMS6cNAKKwTmqEb7w0TiirayfKspH8Kdqbt3P3DGGjGgB2NQRcaoXUgEHq2hQqAMy80dRmiG50XdmOfDycgTGr4iY4V1WyTwX2qaJ9KpWhN9tnvibqjb-2Pgkm3LYMtNmxAJyp6pyp-pczZehw4wBV15eXFXw8THIUAMkMvdpWQy8MKq7nrl2nNioHbAZtDpK_bCURAcTyMs-Q2vGkHVF3a-bTi8j0TakGKQXN0NuN0_2Q68-6eP4_dPEC7bPYWzhh5SHaWy3W7iW6ay9X0-Wih27LiYxX1UN3Tgaj8VkvdkG4Dr8NoGz8cTj-8h1iLTH5
linkProvider	Directory of Open Access Journals
linkToHtml	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V1Lb9QwELZKQcCF9yNQwEjABawmjhPbSAiVLVWrblcItdLeTOzYdKXVpmx2geVH8RsZO8lWy6O3HjgmcSJ78s14Pns8g9CzLM1sTI0lLpeWsDwtiXZOEE6Z5ZZqWeiQXb_PBwMxHMoPa-hndxbGh1V2NjEY6rIyfo18E7AHU40Ad_7tyRfiq0b53dWuhEYDi327-AaUrX6ztw3_9zmlO-8Pe7ukrSpATMbSGWEpNS7PUs1A101CDXMscdrx1Ei4qankVmqgAX51UDNXOq4tE0YWluV5yVP47gV0Eew492SPD_lyTcd74zKR7dmcOBWbNQMCI4ivGQszQRYTsTL_hTIBf_Nt_wzR_G2fNkx_O9f_N8HdQNdaRxtvNZpxE63ZyS10-aANJbiNfgB10GOLj0cz_AKXzYX9HuKCqykeLwDmPnbqNS5wiLr0MrJTXLRZXHDlcD0HQwuqiqv5DIRha-yXtXFvO5Gk8RVsiXtbH_Eh8RskuDnstriDjs5l5HfR-qSa2PsIa1ECAy7AM0kM4xLIWlHoTHgmHpcyMRFKOngo02Zp98VCxipEC6RCNZBSACkVIKVEhF4u3zlpcpSc2fqdR92ypc8vHm5U08-qNVfKgSfqmDF-15QxziTXiaFG08JnA6J5hDY6sKnW6NXqFGkRerp8DObKi7iY2GretBExkFhoc6-B-LInzLP9NI8jJFbAv9LV1SeT0XFIiZ4kEnrJkgi96vTktF__lsWDs4fxBF3ZPTzoq_7eYP8hukqDGqeE5htofTad20fokvk6G9XTx8EOYPTpvPXnF4mwmJ4
linkToPdf	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMw1V3db9MwED-NDk288P0RGGAk4AWsJo6T2EgIjZaJaltVoSFtTyF2bFapakbTAuVP46_jnI9O5WNve-AxiRs519_vfHc-3wE8jcLI-EwbamNpKI_DnCprBU0YN4lhSmaqqq6_nwyH4uhIjjbgZ3sWxqVVtjqxUtR5oV2MvIvYw6VGoDnftU1axKi_--b0C3UdpNxOa9tOo4bInll-Q_etfD3o43_9jLHdd4e997TpMEB1xMM55SHTNo5CxZH3OmCaWx5YZZNQS7ypmEyMVOgSuEih4ja3iTJcaJkZHsd5EuJ7L8EmmuScdWBzNDgYHa8iPM42l4FsTur4oeiWHN0ZQV0HWVwXIp-KtdWwahrwN0v3z4TN33Ztq8Vw99r_LMbrcLUxwclOzZkbsGGmN2HroEkyuAU_0KlQE0NOxnPynOT1hfleZQwXMzJZIgFcVtUrkpEqH9PJy8xI1tR3IYUl5QJVMJKYFIs5CsaUxAW8Sa8fSFpbESYnvZ0P5JC6rRNSH4Nb3oaPF_Lld6AzLabmHhAlcvSNM7RZAs0TiW5clqlIOB_dz2WgPQhaqKS6qd_u2ohM0iqPIBRpDa8U4ZVW8EqFBy9Wvzmtq5ecO_qtQ-BqpKs8Xt0oZp_TRpGlFm1Uy7V2-6kccS8TFWimFctcnSAWe7DdAi9t1GGZnqHOgyerx6jInIizqSkW9Rjho3uLY-7WcF_NhLs4QBj7Hog1IqxNdf3JdHxSFUsPAomz5IEHL1vOnM3r37K4f_5nPIYtpE26PxjuPYArrGJ0SFm8DZ35bGEewmX9dT4uZ48apUDg00UT6BdBW6Lt
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Double+hit+%26+double+expressor+lymphomas%3A+a+multicenter+analysis+of+survival+outcomes+with+CD19-directed+CAR+T-cell+therapy&rft.jtitle=Blood+cancer+journal+%28New+York%29&rft.au=Karmali%2C+Reem&rft.au=Shouse%2C+Geoffrey&rft.au=Torka%2C+Pallawi&rft.au=Moyo%2C+Tamara+K&rft.date=2025-03-26&rft.eissn=2044-5385&rft.volume=15&rft.issue=1&rft.spage=43&rft_id=info:doi/10.1038%2Fs41408-025-01250-8&rft_id=info%3Apmid%2F40140360&rft.externalDocID=40140360
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2044-5385&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2044-5385&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2044-5385&client=summon